Clinical Trial Update: SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial [Phase 2]

View source ↗

Summary

A Phase II trial is evaluating the combination of stereotactic body radiotherapy (SBRT) and lenalidomide for solitary plasmacytoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solitary Plasmacytoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Solitary Plasmacytoma | Phase 2 | Status: RECRUITING